



SDI Review Form 1.6

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_20709
Title of the Manuscript:	Effect of Carboplatin and Methotrexate on Lipid Levels in the Plasma Membrane of MCF-7 Cells and their Association with Cell Motility
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Line 108: It is essential for the authors to include references which have qualified the notion "Major hallmarks of cancer are the abnormalities in phospholipids metabolism".	I would like to thank you first for taking the time to review our manuscript. And giving your comments. Reference Added
	Line 116: It is unclear as to what PC, PI, PE and PS stand for. The authors need to define the abbreviations.	Abbreviations added.
	Line 138: It is unclear as to why the cells were being serum starved during treatment. It is essential for the authors to justify this particular step of the <i>in vitro</i> cytotoxicity assay.	We re-mentioned in materials and methods that MTT assays were conducted first in the presence of fetal bovine serum and no effect on cells was obtained in the presence of either drug added. Hence, experiments were carried later in the absence of FBS where effect of drug was noticed.
	Lines 163 and 173: Abbreviated terms should be expressed in full when used for the very first time.	Done
	Lines 314-325: (i) It is essential for the authors to compare the 24 h IC₅₀ of carboplatin obtained in the present study to those of the previous studies against the same cell line. (ii) It is also essential for the authors to disclose the duration of treatment for the results cited from previous studies.	This was done in discussion part where we explained the difference in IC obtained in our study compared to others. Most treatments were done for 24 hours.
	Lines: 326-335: It is essential for the authors to compare the 24 h IC₅₀ of methotrexate obtained in the present study to those of the previous studies against the same cell line.	Same as above.
	Lines 338-339: It is essential for the authors to justify the basis of claiming "the drugs could have been chelated by the proteins found in the FBS". This is contradicting to Line 138 whereby the authors stated that the cells were being serum starved during treatment.	We re-mentioned in materials and methods that MTT assays were conducted first in the presence of fetal bovine serum and no effect on cells was obtained. Hence, experiments were carried later in the absence of FBS where effect of drug was



SDI Review Form 1.6

		noticed. In discussion, we tried to put the different plausible reasons why drugs may not inhibit cell growth.
	Lines 340-343: Having identified passage number as one of the factors that could have influence the results, it is therefore essential for the authors to disclose the passage numbers of MCF7 used throughout the experiment.	Added in methods.
	Line 399: It is essential for the authors to justify as to why “these decreases were not significant”.	According to statistical analysis.
	It is essential for the authors to include a conclusion at the end of the text.	Done
<u>Minor</u> REVISION comments	The use of drug name should be consistent throughout the manuscript. The authors have to decide to either use the full generic name or the abbreviated name of carboplatin and methotrexate in this paper. For full generic name, carboplatin and methotrexate should be presented as small cap throughout text and captions.	Name replaced as CPT or MTX
	Figures included in this manuscript appear to be of low resolution. It is suggested that the figures be replaced with those of high resolution.	Figures are taken from excel files and added to word.
	Tables: The decimal place of the data should be consistent.	Corrected.
	Line 127: “Cell strain” should be corrected as “Cell line”.	Prefer to use cell strain as cell were derived from a primary culture.
	Lines 151 and 179: The centrifugation speed should be consistently expressed as “x g” throughout the manuscript.	corrected
	Lines 184-185: The authors are advised to revise the format of cited reference.	Reference re-adjusted according to authors’ guidelines.
	Line 214: “the standard deviation” should be corrected as “standard deviation”	done
	Lines 368 and 370: “cell strain” should be corrected as “cell type”	Prefer to use cell strain as cell were derived from a primary culture.
<u>Optional/General</u> comments	Line 388: The authors should consider disclosing the data as supplementary.	We will try to identify each peak in chromatogram. Prefer to keep it for a later manuscript.



SDI Review Form 1.6

	Only about 20% of the references are of the recent 5 years. The authors may want to include more up-to- date references.	Most relevant references available has been cited.
--	---	--